{"id":"W2506500153","doi":"10.1158/1538-7445.am2016-ct079","title":"Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; T790M; Internal medicine; Tolerability; Oncology; Progressive disease; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Lung cancer; Clinical trial; Epidermal growth factor receptor; Chemotherapy; Cancer; Adverse effect; Gefitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001578626,0.002204758,0.002411824,0.0005402008,0.0005196976,0.001098125,0.00130047,0.001774657,0.01019684],"category_scores_gemma":[0.0008783768,0.0007892738,0.001469805,0.0005318956,0.001164027,0.001290725,0.0004870837,0.004312402,0.002552909],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001022204,"about_ca_system_score_gemma":0.001609259,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00123393,"about_ca_topic_score_gemma":0.002548782,"domain_scores_codex":[0.9994656,0.0002869302,0.00002523278,0.00007767515,0.00004398392,0.0001005411],"domain_scores_gemma":[0.9992852,0.0001004249,0.0001085715,0.00003438543,0.00004379857,0.0004277106],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8818414,0.05016941,0.004135339,0.0007027508,0.00088687,0.000268641,0.000135931,0.001140132,0.0164196,0.0002369984,0.004365722,0.03969727],"study_design_scores_gemma":[0.6495798,0.3398506,0.005960674,0.00003714793,0.0003108593,0.0001966871,0.00003258168,0.0006783719,0.001479524,0.000117902,0.001728721,0.00002719341],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9829791,0.002429456,0.0005300632,0.0009955001,0.0002210712,0.004447251,0.002829217,0.0001902357,0.005378021],"genre_scores_gemma":[0.9773611,0.00212945,0.001243763,0.001735802,0.0003889195,0.003145591,0.005059623,0.00004438266,0.008891453],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01019684,"threshold_uncertainty_score":0.0341118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02648798318716302,"score_gpt":0.3484391199797316,"score_spread":0.3219511367925686,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}